1. Comparison of the pharmacokinetics and pharmacodynamics of LY2963016 insulin glargine and EU- and US-approved versions of Lantus insulin glargine in healthy subjects: three randomized euglycemic clamp studies;Linnebjerg;Diabetes Care
2. European Medicines Agency. Guideline on non-clinical and clinical development of similar biological medicinal products containing recombinant human insulin and insulin analogues [Internet], 2015. Available from http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2015/03/WC500184161.pdf. Accessed 12 August 2015
3. Center for Drug Evaluation and Research, U.S. Food and Drug Administration. Guidance for industry: diabetes mellitus: developing drugs and therapeutic biologics for treatment and prevention [Internet], 2008. Avaliable from http://www.fda.gov/downloads/Drugs/.../Guidances/ucm071624.pdf. Accessed 12 August 2015
4. Contribution of postprandial versus interprandial blood glucose to HbA1c in type 1 diabetes on physiologic intensive therapy with lispro insulin at mealtime;Ciofetta;Diabetes Care,1999
5. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro;Lepore;Diabetes,2000